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Key Clinical Message
Basal cell carcinoma can be misdiagnosed as acne; thus, carcinoma should be
considered in treatment-resistant acne. Although rare, neglected basal cell
carcinoma increases the risk of metastasis.
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Introduction
Basal cell carcinoma (BCC) is the most common type
of skin cancer. It grows slowly and originates from the
basal layer of epidermis and hair follicles. Initially, it
grows in the epidermis and superficial dermis, but
when neglected, invasive growth and local tissue
destruction may occur [1]. BCCs are treated with curet-
tage, excision, radiotherapy, or other topical/dermato-
logical treatment [2, 3]. Metastatic basal cell carcinoma
(MBCC) is very rare with a reported incidence between
0.0028% and 0.5% [4]. The true incidence is, however,
probably even lower, since the frequency of BCC is
considered to be substantially underreported [5]. The
mortality associated with BCC is below 1% [6]. In
MBCC, average survival is reported to be 3.6 years in
patients with metastases to lymph nodes, while metasta-
sis to bone, liver, or lungs only convey an average sur-
vival about 8–14 months [4, 7]. Acne is a common
skin disease characterized by blockage and/or inflamma-
tion of hair follicles and their sebaceous gland. Severe
acne presents comedones and abscesses that may persist
for months and even longer if untreated. Acne is typi-
cally localized in the skin surface of the face, but the
chest, back, and upper extremities are often involved as
well [8]. Treatment options for acne include topical
anti-acne preparations, lasers, lights, tetracyclines, and
isotretinoin. The similarities in presentation and local-
ization between BCC and acne may cause misdiagnosis.
However, in contradiction to BCC, acne usually
respond to the treatment at least to some extent [8].
We present a case of MBCC to the right axillary lymph
nodes 6 years following excision of primary tumor ini-
tially mistaken as acne.
Case Report
In April 2014, a 53-year-old Caucasian male presented
with a subcutaneous swelling in his right axilla, which
had been progressing over a 6-month period. Blood tests
were unremarkable. He had a long history of multiple
small BCCs in the face and torso. Treatments had varied
from x-ray therapy, surgery, and curettage. The patient’s
father and older brother had also been treated for multi-
ple BCCs. The patient had a Fitzpatrick skin type 1. The
patient was otherwise healthy and had no environmental
risk factors such as immunosuppression, exposure to X-
ray, arsenic or excessive sun use.
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An ultrasound-guided needle biopsy of the enlarged
lymph node was performed and the pathology report
concluded MBCC. The patient was referred to our plastic
surgery department where a skin examination showed no
suspicious tumors and the remaining lymph node stations
were without clinical pathology. Full body positron emis-
sion tomography (PET) with 18-Flouro-dexocyglucosen
(FDG) and computer tomography (CT) only showed a
marginally enlarged FDG-positive lymph node in the right
axilla measuring 11 9 9 mm. This was consistent with
the clinical presentation and pathology report. A right
axillary lymph node dissection was performed, and the
pathology report confirmed MBCC in three of the 23
excised lymph nodes.
As mentioned, the patient had a history of multiple
minor BCCs, and especially one episode of cutaneous
BCC located on the right pectoral region was interesting
and was considered as the BCC, which later metastasized.
This BCC had clinically been diagnosed as acne in 2006.
The patient developed the acne at the age of 45 years and
was treated successfully with systemic isotretinoin by a
dermatologist for a period of 18 months. The patient did
not receive X-ray treatment for the acne. However, an
element on the right pectoral region did not respond to
the treatment as the only one. A biopsy was taken from
the element, which at the time measured
30 9 20 9 9 mm and histological examination deter-
mined infiltrative BCC. The carcinoma was excised with
an 8-mm margin including some subcutaneous fat, but
this excision was not radical. Re-excision with an addi-
tional 5-mm margin and in depth to the muscle fascia
was found with free margins. The wound was closed
directly, and no further treatment was indicated at that
time.
We believe that this BCC in the right pectoral region
was the one that spread to a lymph node in the right
axilla. Since the patient had a history of multiple BCCs,
we can of course not be absolutely certain of this; how-
ever, none of the previous BCCs had been at a substantial
size like the one in question, and none had been in the
right pectoral/dorsal region (or right side of the neck),
which would be expected due to the drainage pattern to
the right axilla.
Because of the family predisposition to BCCs, the
patient was now offered genetic testing for the Basal Cell
Nevus Syndrome (#109400, http://www.omim.org/), but
the patient declined.
Currently, the patient is followed with full skin exami-
nation and clinical evaluation of the lymph node basins
quarterly, and after 2 years biannually for a total of
5 years. PET/CT scans performed 3 and 9 months post-
operatively was unremarkable. The patient remains free
from recurrence 18 months after surgery.
Discussion
We reviewed the past 10 years of scientific literature and
identified 15 cases of MBCC (Table 1). As shown in
Table 1, the most common metastatic sites were lymph
nodes (n = 12), lungs (n = 2), and bones (n = 2), which
confirms the findings of Ganti and colleagues, who in
2011 presented a systematic review [9]. The majority of
primary BCCs that metastasize have been reported to
originate from the head and neck [10]. Contrary, as pre-
sented in Table 1, we found five cases with primary
tumor on head and neck, while six cases had primary
tumor on the truncus as in the current case. Increased
risk of metastasis is associated with large size of primary
tumor, infiltrating type of BCC, recurrent and neglected
tumors, and perineural invasion [4]. Snow et al. [11]
reported an association of increased risk of MBCC origi-
nating from neglected BCC misdiagnosed as acne, which
was exactly the situation for our case.
In the literature, the median duration between the
diagnosis of the primary tumor and the occurrence of
metastasis was 18 month (range 1–48 months, N = 9).
Two patients had metastases at the time of diagnosis [12,
13]. In our case, the metastasis occurred approximately
6 years after diagnosis of the primary tumor. This corre-
lates well with previous cases [7, 12]; an MBCC review
found the estimated median interval from tumor appear-
ance to metastasis to be 9 years [9].
The reported median disease free survival from MBCC
of reviewed cases (n = 9) was 18 month. Our patient has
been free of recurrence for 18 months so far. Ganti et al.
[9] reported that the prognosis of patients with MBCC was
poor with an average survival time of approximately
3.6 years in patients with regional lymph nodes metastases,
and 10 months in those with hematogenous metastases
(bone, lungs, and other internal organs). Surgery is still
considered the first line of treatment [14, 15] (Table 1).
Our review is presented in Table 1; six patients had surgery,
two patients underwent surgery and radiotherapy, while
one patient received surgery and chemotherapy. Two
patients underwent all treatment modalities. Additionally,
two patients received chemotherapy alone, one of which
refused surgery, while the other patient, who died within
6 months, had such an extended progression of disease that
surgery was not indicated. One patient received vismodegib
after surgery and chemotherapy due to insufficient effect of
chemotherapy. The molecule vismodegib is an inhibitor of
the Hedgehog pathway and was approved in January 2012
by the US Food And Drug Administration. The use of vis-
modegib is recommended for the treatment of adults with
metastatic BCC, or with locally advanced BCC, which has
recurred following surgery or which is not eligible for sur-
gery or radiation therapy [16].
602 ª 2016 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
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Marghoob et al. [17], found that patients diagnosed
with BCC had a 45.2% risk of developing another BCC
within 5 years. This correlates with the NCCN guidelines
stating that 30–50% of patients with BCC will develop
another BCC within 5 years [15]. Less than 1% of BCCs
spread to another site in the body. In such cases, pro-
longed or lifelong follow-up care including regular skin
screening and PET/CT is recommended [14, 15].
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